Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse by ONESTI, Concetta Elisa et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=koni20
OncoImmunology
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/koni20
Blood eosinophilic relative count is prognostic for
breast cancer and associated with the presence of
tumor at diagnosis and at time of relapse
Concetta Elisa Onesti , Claire Josse , Delphine Boulet , Jérôme Thiry , Barbara
Beaumecker , Vincent Bours & Guy Jerusalem
To cite this article: Concetta Elisa Onesti , Claire Josse , Delphine Boulet , Jérôme Thiry ,
Barbara Beaumecker , Vincent Bours & Guy Jerusalem (2020) Blood eosinophilic relative count is
prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of
relapse, OncoImmunology, 9:1, 1761176, DOI: 10.1080/2162402X.2020.1761176
To link to this article:  https://doi.org/10.1080/2162402X.2020.1761176
© 2020 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 13 May 2020. Submit your article to this journal 
View related articles View Crossmark data
ORIGINAL RESEARCH
Blood eosinophilic relative count is prognostic for breast cancer and associated with
the presence of tumor at diagnosis and at time of relapse
Concetta Elisa Onestia,b, Claire Josse a,b, Delphine Bouletb, Jérôme Thiryb, Barbara Beaumeckerc, Vincent Boursb,d,
and Guy Jerusalem a,c
aMedical Oncology Department, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium; bLaboratory of Human Genetics, GIGA Institute, Liège,
Belgium; cFaculty of Medicine, Liège University, Liège, Belgium; dDepartment of Human Genetics, Centre Hospitalier Universitaire Sart-Tilman, Liège,
Belgium
ABSTRACT
Background: Cancer outcome is associated with circulating immune cells, including eosinophils. Here we
analyze the relative eosinophil count (REC) in different breast cancer subtypes.
Methods: Stage I–III breast cancer patients were included in the study and classified as REC-high vs low
(cutoff 1.5%) or relative lymphocyte count (RLC)-high vs low (cutoff 17.5%). The co-primary endpoints
were the breast cancer-specific survival (BCSS) or the time to treatment failure (TTF) in the REC groups.
Results: Overall 930 patients were included in the study. We observed a benefit for REC-high vs REC-low in
TTF (HR 0.610, 95% CI 0.458–0.812), and in BCSS (HR 0.632, 95% CI 0.433–0.923). Similarly, we observed
a better TTF (HR 0.421, 95% CI 0.262–0.677) and BCSS (HR 0.350, 95% CI 0.200–0.614) in RLC-high vs low.
A lower relapse rate was observed in the REC-high vs REC-low group (17.1% vs 24.7%, p = 0.005), not
confirmed in the multivariate analysis. A lower median REC at baseline and at relapse was observed
compared to REC after surgery and during cancer-free follow-up (p < .0001).
Conclusions: REC could be a new promising, affordable and accessible predictive and prognostic
biomarker in all breast cancer subtypes.
ARTICLE HISTORY
Received 20 March 2020
Revised 22 April 2020






Breast cancer is the most common cancer and the leading cause
of cancer-related death in women worldwide, with more than
2 million new cases and 626 679 deaths per year.1 The standard
treatment for early breast cancer is multidisciplinary, with
a combination of surgery, radiotherapy and systemic treatment
(chemotherapy, hormonotherapy and targeted therapy).
Some reports have suggested a role of the immune system in
breast cancer development, showing an association between
tumor-infiltrating lymphocytes and chemotherapy response, in
particular in triple-negative breast cancer (TNBC) and in hor-
mone receptor-negative/HER2-positive breast cancers.2–5
Various immune cells infiltrate tumor tissue and stroma.
Specific immunologic profiles are associated with histologic
characteristics, such as hormone receptor expression, HER2
overexpression and tumor grade, or with response to
treatment.6,7 In general, CD8+ cytotoxic T lymphocytes are
associated with a good prognosis, while Treg cells are asso-
ciated with an unfavorable outcome.5 Chemotherapy sensitiv-
ity and cancer outcomes appear to be affected by circulating
immune cells, including neutrophils, lymphocytes and eosino-
phils. Notably, pre-treatment lymphopenia is associated with
poor survival and is predictive of tumor recurrence.8–12
Similarly, the neutrophil/lymphocyte ratio, the platelet/lym-
phocyte ratio and the lymphocyte/monocyte ratio were
described to have prognostic value in breast cancer.13,14
The role of peripheral eosinophil count has been studied
mainly in melanoma and in lung cancer patients treated with
immunotherapy.15–25 Concerning breast cancer, less studies
have been published so far and their role is still controversial.
A first study, published in 1983, showed that high baseline
eosinophil count was associated with a lower recurrence rate
in 419 breast cancer patients.8 On the other hand, in a smaller
retrospective series of 62 HER2-positive breast cancer patients
treated with trastuzumab a survival benefit for patients with
lower baseline eosinophil count was observed.9 Recently, in our
previous retrospective study, conducted on 112 TNBC and
hormone receptor-negative/HER2-positive breast cancer
patients receiving neoadjuvant treatment, we observed
a positive association between baseline relative eosinophil
count (REC) with pathological complete response and survival
rate.26 Moreover, we observed an increase in relative circulat-
ing eosinophils, that remain stable until at least 1 year (y) after
curative treatment. A statistically significant reduction of rela-
tive eosinophil count (REC) at relapse timepoint was observed
in a small cohort of 23 patients, suggesting that the tumor
could affect the peripheral eosinophil count, with still
unknown mechanisms.26
Stage I–III breast cancer patients of all the subtypes receiv-
ing curative surgery with or without chemotherapy, targeted
therapy and hormonotherapy have been included in this retro-
spective report. The aim of this work was to study the impact of
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eosinophil count on outcome and its variation during disease
course in all breast cancer subtypes.
Materials and methods
Patients selection
Patients with a histologically proven stage I–III breast cancer,
treated between January 1999 and December 2018 at
University Hospital of Liège, were retrospectively included in
this study. All the patients included in the analysis were in good
clinical conditions (Performance Status 0–2), had adequate
organ function at diagnosis and have been treated with surgery
with or without additional treatment (chemotherapy, radio-
therapy, target therapy and hormonotherapy), according to
local guidelines.
Patients without a baseline hematological evaluation includ-
ing REC, with a diagnosis of another primary tumor during the
5 y before the breast cancer diagnosis, with a metastatic disease
at diagnosis or with a Tis breast tumor were excluded from the
trial.
This study was performed in compliance with the Helsinki
Declaration and was approved by the local Ethics Committee
with the reference N 2020/53. All the patients were recruited at
the University Hospital of Liège – CHU Liege. As
a retrospective and non-interventional study, informed con-
sent is not required. Medical records were analyzed
anonymously.
Data collection
For all the patients, the following data were collected: age at
diagnosis; histological characteristics at baseline such as estro-
gen receptor (ER), progesterone receptor (PgR), HER2 status,
Ki67, histotype, Scarff-Bloom-Richardson tumor grade (G);
TNM stage and tumor size at baseline; type of treatment;
presence of relapse confirmed by radiological imaging and/or
histological analysis; hematological lab tests at seven different
timepoints (at diagnosis, after surgery, 1 y after surgery, 2 y
after surgery, 5 y after surgery, 10 y after surgery and at relapse,
if observed). Blood analysis performed during infection, after
a diagnosis of a secondary cancer, for follow-up of hematologic
diseases, during chemotherapy and after relapse was not
included in the database.
All the data listed below were done for medical purposes
and retrospectively collected by a medical oncologist.
Immunohistochemistry was used the determine ER, PgR,
HER2 and Ki67; fluorescent in situ hybridization (FISH)
was used to confirm HER2 status in selected cases; histology
and tumor grade were determined by an experienced
pathologist on hematoxylin-eosin stained tumor sample at
baseline. TNM stage was determined with radiological ima-
ging (Rx mammography, breast ultrasound, breast IRM,
thorax and abdominal CT scan, where clinically required)
and on surgical samples for patients not receiving neoadju-
vant chemotherapy as primary approach. Hematological lab
tests, too, were routinely performed for medical purposes.
The white blood cell count was done through the hematol-
ogy analyzer Sysmex XE-5000 based on fluorescent flow
cytometry technology. Relative count was calculated for
eosinophils and lymphocytes on the total count of white
blood cells.
Survival data were collected with a data cutoff in
October 2019. We considered as time-to-event the time to
treatment failure (TTF), defined as the interval between diag-
nosis and loco-regional, contralateral or metastatic relapse or
death by breast cancer, and the breast cancer-specific survival
(BCSS), defined as the interval between diagnosis and death by
breast cancer.27,28
Statistical analyses
Statistical analyses and graphs were done using IBM SPSS
Statistic v25, MedCalc v19.1.5 and Prism GraphPad 5.
To define the group of patients as REC-low/high and rela-
tive lymphocyte count (RLC)-low/high, the cutoff of 1.5% for
REC has been used, where <1.5% were considered REC-low
and ≥1.5% REC-high, according to similar studies conducted
on melanoma patients.18 Analogously, for RLC the cutoff of
17.5% has been used, with value <17.5% considered as RLC-
low and ≥17.5% as RLC-high.18 The REC and the RLC have
been combined in a unique biomarker, the eosinophil-
lymphocyte product (ELP), by multiplying the REC and the
RLC. The best cutoff for ELP was calculated by drawing a ROC
curve for relapse and death by means of the Youden index.
Finally, we selected as threshold to classify patients as ELP-high
/low the mean value between the two cutoffs previously calcu-
lated, where values < this cutoff were considered as ELP-low
and ≥ as ELP-high.
The two co-primary endpoints for this study are the asso-
ciation between TTF and BCSS and relative eosinophil count
(REC-low vs REC-high groups) in the whole cohort of patients.
The secondary endpoints are the association between baseline
REC, RLC and ELP with relapse; the TTF and BCSS according
to RLC and ELP at baseline and according to REC, RLC and
ELP after surgery; the variations in REC and RLC after surgery,
during follow-up and at relapse. A subgroup analysis according
to age < or ≥65 y, treatment with chemotherapy, anti-HER2,
hormonotherapy and radiotherapy and according to histology
(ductal or luminal) and to breast cancer subtype (Luminal A,
Luminal B, HER2-enriched, TNBC) was performed.
The association between patient baseline characteristics
expressed as dichotomous variables (ER, PgR, HER2, Ki67,
breast cancer subtype, histology, stage, T stage, N stage,
tumor grade, lymphovascular invasion and BRCA status) and
REC was tested by means of the Chi-Square test. Spearman test
was used to analyze the correlation between age, tumor size
in mm, ER, PgR and Ki67 in percentage and REC as
a continuous variable.
Kaplan–Meier and Log-Rank tests were used to analyze
survival. The HR for TTF and BCSS was calculated with
a Cox Regression. The 5-y and the 10-y TTF and BCSS were
calculated from the survival tables.
The Chi-Square test was used to calculate the association
between relapse and dichotomous variables as REC, RLC,
ELP, ER status, PgR status, HER2 status, Ki67 < or ≥20%,
T stage, N stage, tumor grade, histology, lymphovascular
invasion, type of treatment and BRCA status. The Mann–
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Whitney U test was used for the continuous variable as age,
ER and PgR expressed in percentage, Ki67, tumor size, plate-
let count, relative and absolute neutrophil, lymphocyte,
monocyte, eosinophil and basophil count. Sequential binary
logistic regression with forward stepwise selection of variables
based on likelihood ratio was performed for relapse, including
in the test all the variables with a p value ≤ 0.1 in the Chi-
Square or Mann–Whitney test. For variables significant in
both the Chi-Square and the Mann–Whitney test we chose
the variable with the best p value. For the variables with the
same p value in both univariate tests, we chose the continuous
variable.
We evaluate the variations in the REC and RLC distribu-
tions from the baseline, during follow-up and at relapse using
a Friedman test for seven different timepoints: at diagnosis,
after surgery, 1 y after surgery, 2 y after surgery, 5 y after
surgery, 10 y after surgery and at relapse, if occurs. The patients
with or without relapse were analyzed separately.
A comparison by pairs of the different timepoint was done
through a Bonferroni–Dunn multiple comparison post hoc
test.
Results
Overall 930 patients with a diagnosis of stage I–III breast
cancer between January 1999 and December 2018 were
included in our study. The median follow-up was of
104 months (range 6–245 months) with a data cutoff in
October 2019. The median age at diagnosis for the whole
cohort was of 61 y (range 25–97).
Using the cutoff of 1.5% for REC, we classified 393 patients
(42.3%) as REC-low and 537 patients (57.7%) as REC-high at
baseline. According to the cutoff of 17.5% for RLC, 53 patients
(5.7%) were classified as RLC-low and 877 (94.3%) as RLC-
high at baseline.
The baseline characteristics in the group of patients REC-low
and REC-high are reported in Table 1. Overall 40.9% of patients
were classified as Luminal A, 31.8% as Luminal B, 7.1% as
HER2-enriched and 18.8% as TNBC, with a lower rate of
TNBC (14.3% vs 22.6%) and a higher rate of Luminal A (46%
vs 33.8%) in the REC-high group compared to REC low-group
(p < .0001). In the REC-high group, we observed also a higher
rate (49.7%) of tumor with Ki67 lower than 20% compared to
REC-low (40.7%) patients (p=0.006). The REC-high and low
groups were well balanced for all the other baseline character-
istics, notably for HER2 status, stage at diagnosis, T, N, G,
histology lymphovascular invasion and BRCA mutation. REC
is significantly correlated with age with a Spearman correlation
coefficient of 0.145 (p < 0.0001). No significant correlations were
observed between REC and tumor size in mm, ER, PgR and Ki67
as continuous variables (Supplementary materials, Table 1).
All 930 patients underwent surgery. Additional treatments,
according to cancer characteristics and physician choice, were
also performed, in particular, 552 patients out of 930 received
neoadjuvant and/or adjuvant chemotherapy, 156 patients
received anti-HER2 treatment, 736 radiotherapy and 676 hor-
monotherapy, as reported in SupplementaryMaterials (Table 2).
The number of patients included in the survival analysis was
826; 73 patients were excluded from the analysis due to death
for other causes than breast cancer and 31 were lost at follow-
up. At data cutoff, we observed 189 relapses, 97 in the REC-low
group and 92 in the REC-high group, and 109 deaths, 56 in the
REC-low and 53 in the REC-high group. Out of the 189
relapses, 28 were loco-regional, 18 in the contralateral breast












































































































































































































































































Abbreviations: REC, Relative Eosinophil Count; N, Number; ER, Estrogen Receptor;
PgR, Progesterone Receptor; TNBC, Triple-Negative Breast Cancer.
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and 138 metastatic. The information about the site of relapse
was missing for 5 patients. We observed a longer TTF for
patients classified at baseline as REC-high compared to REC-
low patients (5-y TTF 84% vs 74%, p=0.001; HR 0.610, 95% CI
0.458–0.812), as well as a better BCSS (5-y BCSS 90% vs 86%,
p=0.021; HR 0.632, 95% CI 0.433–0.923) (Figure 1(a–b),
Supplementary Materials Table 3). Alike, for patients classified
as RLC-high at baseline compared to RLC-low group we
observed a better TTF (5-y TTF 75% vs 51%, p < .0001; HR
0.421, 95% CI 0.262–0.677) and BCSS (5-y BCSS 89% vs 74%,
p < .0001; HR 0.350, 95% CI 0.200–0.614) (Figure 1(c–d) and
Supplementary Materials Table 3). The separation of the two
curves is more pronounced using the RLC as parameter com-
pared to REC in both TTF and BCSS, even though the small
sample size of only 53 patients for the RLC-low group.
We combined the eosinophils with the lymphocytes in the
variable ELP, as proposed in our previous study.26 We calculate,
by means of the ROC curve and the corresponding Youden
index, the best cutoff to predict relapse and death for breast
cancer, which are, respectively, 38.97 and 34.04. Then, we use
the mean value of 36.5 between these two calculated indices as
cutoff for our analysis. Using this cutoff, we classified 343
patients as ELP-low and 587 as ELP-high at baseline. We
observed a better TTF (5-y TTF 84% vs 74%, p=0.003; HR
0.646, 95% CI 0.484–0.861) and BCSS (5-y BCSS 90% vs 86%,
p=0.003; HR 0.572, 95% CI 0.392–0.834) for ELP-high group
(Figure 1(e–f) and Supplementary Materials Table 3).
Baseline REC is also predictive of relapse in univariate
analysis, with a higher incidence of breast cancer recur-
rence in the group REC-low than in the group REC-high
(24.7% vs 17.1%, p=0.005). Similar results were observed
for RLC (35.8% vs 19.4% in RLC-low and high, respec-
tively, p=0.004) and ELP (24.8% vs 17.7% in ELP-low and
high, respectively, p=0.01) in the univariate analysis
(Supplementary materials, Table 4). The multivariate ana-
lysis showed that the only independent variable predictive
of relapse was the N stage with an odds ratio (OR) of 2.392,
95% CI, 1.324–4.321 (p=0.004) (Supplementary materials,
Table 5).
A survival analysis performed according to REC, RLC and
ELP after surgery showed a statistically significant result only for
BCSS according to REC (5-y BCSS 86% vs 78% in REC-high vs
REC-low group, p=0.025; HR 0.583, 95% CI 0.361–0.940) and
ELP (5-y BCSS 86% vs 79% in ELP-high vs ELP-low group,
p=0.018; HR 0.571, 95% CI 0.357–0.913). However, we observe
the same trend of benefit for TTF in REC-high and ELP-high
group, and in term of TTF and BCSS for RLC-high group, with-
out reaching the statistical significance (Supplementary Materials,
Table 6).
In the subgroup analysis, we classified patients according to
the age, the treatment with chemotherapy, anti-HER2, radio-
therapy or hormonotherapy, according to the histology and the
subtype. We observed an HR in favor of the group REC-high at
baseline for all the subgroups for TTF (Figure 2a) and for all
the subgroups with the exception of the lobular histology, the
Luminal A and the Luminal B subtypes for BCSS (Figure 2b).
In these cases, the HR showed a trend in favor of the group
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Finally, we analyzed the variation of blood parameters dur-
ing the follow-up. In the group of patients not experiencing
a relapse (n = 741), we observed a lower median REC at
diagnosis (1.7%) that increase after surgery (2.6%) and remain
stable until 10 y of follow-up (2.6% at 1 y and at 5 y of follow-
up, 2.5% at 2 y and at 10 y of follow-up) (Figure 3a). The
variation in REC distribution was statistically significant
between the different timepoints according to Friedman test
(p < .0001) and according to post-hoc multiple comparison
Bonferroni–Dunn test. In the group of patients showing
Figure 1. TTF and BCSS according to baseline REC, RLC and ELP. Abbreviations: REC, Relative Eosinophil Count; RLC, Relative Lymphocyte Count; ELP, Eosinophil-
Lymphocyte Product; TTF, Time to Treatment Failure; BCSS, Breast Cancer-Specific Survival; HR, Hazard Ratio. Kaplan–Meier curves in the group REC-low and REC-high at
baseline for TTF (a) and BCSS (b); in the group RLC-low and RLC-high at baseline for TTF (c) and BCSS (d); for the group ELP-low and ELP-high at baseline for TTF (e) and
BCSS (f). The corresponding p value calculated by means of the Log-Rank test (L-R) and the HR is reported on each survival curve.
Table 3. REC variation in the cohort of patients without relapse according to subtype.
REC baseline REC post-surgery
REC 1y
Follow-up REC 2y follow-up REC 5y follow-up REC 10y follow-up Friedman test
Luminal A N 325 225 243 239 188 91
Median 1.8% 2.7% 2.6% 2.7% 2.6% 2.6% < 0.0001
SD 1.882 2.580 1.710 1.757 1.578 1.733
Luminal B N 236 181 206 187 129 45
Median 1.6% 2.5% 2.8% 2.5% 2.9% 2.5% < 0.0001
SD 1.666 2.231 2.299 2.267 1.510 1,405
HER2-enriched N 50 35 39 32 23 12
Median 1.8% 2.8% 2.8% 2.1% 2.7% 3.4% <0.0001
SD 3.573 2.352 2.028 1.147 1.360 1.309
TNBC N 115 81 102 89 62 19
Median 1.4% 2.8% 2.5% 2.4% 2.1% 2.7% < 0.0001
SD 1.502 2.190 1.680 1.364 1.430 2.945
Abbreviations: REC, Relative Eosinophil Count; y, years; N, Number; SD, Standard Deviation; TNBC, Triple-Negative Breast Cancer.
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a relapse (N = 189), we observed a lower median REC at base-
line (1.4%) and at relapse timepoint (1.5%), but a higher value
after surgery (2.5%) and during cancer-free follow-up (2.5% at 1
y and at 5 y of follow-up, 2.7% at 2 y, and 2.1% at 10 y of follow-
up) (Figure 3b). The Friedman and the post-hoc Bonferroni–
Dunn test confirmed that the differences are statistically signifi-
cant from baseline and from the relapse time with the other
timepoints, with the only exception for the 10 y of follow-up,
probably due to the insufficient number of observations at this
timepoint. The details of REC and p value for comparisons at
each timepoint are reported in Table 2.
Similarly, we observed a lower absolute eosinophil count at
baseline and at relapse, but we did not reach the statistical
significance in the comparison by pairs, even though the
Friedman test was statistically significant (p < .0001). This is
probably due to the low absolute variation of eosinophil count,
considering that they are rare cells in normal conditions.
The differences in the distribution of RLC during the fol-
low-up in the group of patients with and without relapse are
statistically significant (p < .0001 with Friedman test in both the
groups). In particular, we observed a lower median RLC after
surgery (24.8% in patients without relapse and 24.5% in
patients with relapse) compared to the baseline (29% and
27.4%, respectively) and at relapse timepoint (23.4%). The
difference in the distribution of RLC during the cancer-free
follow-up seems not to have any clinical relevance, being the
median value oscillating between 27.2% and 31% for patients
without relapse, and between 26.6% and 32.9% for patients
with relapse (Supplementary Materials, Tables 7 and 8).
Interestingly, when considering the four breast cancer sub-
types separately, we observed the same trend for REC variations
in all the subgroups, with lower values in presence of cancer, i.e.
at diagnosis and at relapse timepoints, than during cancer-free
follow-up (Tables 3 and 4). The Friedman test showed that the
differences are statistically significant in both the patients
experiencing a relapse and the patients without a relapse.
Discussion
Eosinophils are a subset of granulocytes, generally involved in
parasite infections and in allergic reactions. Their role has been
studied in cancer, where they exert a protumorigenic or
antitumorigenic role, acting with regulatory functions toward
other immune cells or showing a direct cytotoxic activity.29
Recent studies showed that tumor-infiltrating eosinophils are
able to secrete chemokines that attract CD8+ T cells into the
tumor, induce vasculature normalization and M1 macrophage
polarization, with consequent promotion of inflammation and
phagocytic functions.30 Moreover, eosinophils express the
major histocompatibility complex I and II (MHC I and II) on
their cell surface, by which they can act as antigen-presenting
cells, and they express costimulatory molecules, such as CD86,
CD40, CD40 L and CD28, by which they can directly stimulate
T cells.29,30 In addition, in a recent study, Mattes et al. showed
that Th2 cells are responsible for the inhibition of metastases of
melanoma in mice, through eosinophil recruitment into the
tumor.31
Eosinophils could also act in a protumorigenic manner,
promoting metastases through the secretion of metalloprotei-
nase 9, promoting angiogenesis and tissue healing via growth
factors (VEGF, FGF, PDGF) and polarizing macrophage to M2
phenotype with IL-4/IL-13 production.29,32
Tumor-associated tissue eosinophilia was widely studied in
various cancer types, mainly in head and neck carcinoma, in
which an increase in eosinophil count in non-metastatic cases
compared to metastatic carcinomas was reported.33 The impact
of tumor-associated tissue eosinophilia on cancer prognosis is
controversial, with opposite results in different studies.34,35
Eosinophil infiltration of breast tumor is not frequently
observed. In a study conducted by Samoszuk and colleagues,
the eosinophil peroxidase within or around the tumor has been
observed in about 88% of breast cancer, but in none of the
benign breast tissue analyzed.36 In a transcriptomic study,
conducted on almost 11 000 breast tumors, a computational
approach (CIBERSORT) was used to study the immune infil-
tration at tumor site. This study showed that eosinophils were
significantly associated with a better outcome in ER-positive
patients, but not with an improved response to neoadjuvant
chemotherapy.37 In addition, diagnostic core needle biopsies
induce a selective recruitment of inflammatory cells, with an
accumulation of eosinophils, and the enhancement of cancer
cell proliferation in the adjacent area.38
Several authors studied eosinophils’ role in cancer in pre-
clinical models. Injection of IL-33 in mice bearing B16-F10





follow-up REC 2-y follow-up REC 5-y follow-up REC 10-y follow-up REC relapse Friedman test
Luminal A N 55 39 40 38 24 1 43
Median 1.5% 2.5% 2.4% 2.5% 2.25% 2.1% 1.6% 0.038
SD 0.979 1.602 1.497 1.246 0.947 - 1.263
Luminal B N 60 47 42 32 11 - 54
Median 1.5% 2.1% 2.1% 2.7% 3% - 1.2% 0.008
SD 1.378 2.507 2.578 1.879 1.366 - 1.681
HER2-enriched N 16 13 9 4 2 - 13
Median 1.45% 2.6% 3.6% 3.6% 1.3% - 0.9% 0.047
SD 1.529 1.860 2.140 3.123 0.283 - 1.688
TNBC N 50 37 27 19 5 2 42
Median 1.4% 2.5% 2.8% 2.9% 3.4% 2.7% 1.7% 0.001
SD 1.018 1.788 1.456 1.224 1.743 0.990 1.421
Abbreviations: REC, Relative Eosinophil Count; y, years; N, Number; SD, Standard Deviation; TNBC, Triple-Negative Breast Cancer.
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melanoma resulted in reduced tumor growth associated with
intratumoral accumulation of CD8+ T cells and eosinophils,
reduction of myeloid-derived suppressor cells, higher expres-
sion of chemokines attracting eosinophils and CD8+ T cells,
and higher expression of the activation markers for CD8+ and
NK, CD107 and IFNγ, in the tumor and in the spleen.39 In
favor of eosinophils’ activity against cancer, they observed that
a concomitant depletion of eosinophils abolishes the antitumor
effect of IL-33.37 Moreover, an intranasal administration of IL-
33 reduces the number of tumor metastases to the lung
through eosinophil recruitment, without involving CD8+ and
NK cells.39 Concerning breast cancer, IL-33 can inhibit lung
cancer metastasis in Balb/c mice injected with 4T1-Luc cells,
promoting the production of TNF-α by macrophages, that
induce the expression of ST2, the IL-33 receptor, on NK cells,
leading to their activation.40 IL-33 promotes also the produc-
tion of CCL5 by eosinophils and CD8+ T cells that recruit NK
cells at tumor site.40 In other studies, IL-33 administration in
breast cancer-bearing mice induces tumor progression through
intratumoral accumulation of monocytic myeloid-derived
Figure 2. Subgroup analysis for TTF and BCSS according to baseline REC. Abbreviations: REC, Relative Eosinophil Count; TTF, Time to Treatment Failure; BCSS, Breast
Cancer-Specific Survival; HR, Hazard Ratio. Forest plot for TTF (a) and BCSS (b) in baseline REC-high and low patients according to age, histology, subtype and type of
treatment (chemotherapy, anti-HER2 treatment, radiotherapy and hormonotherapy). An HR < 1 indicates a benefit in the REC-high group, while an HR ≥ 1 indicates
a benefit in the REC-low group.
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suppressor cells (MDSC) and Foxp3+ Tregs cells, reducing the
cytotoxicity and the tumor infiltration by NK cells, inducing
cell proliferation and blood vessel density.41,42 Intravenous or
intraperitoneal administration of IL-17E (IL-25) in a variety of
xenograft tumor models, including breast cancer, showed an
antitumoural activity alone or in combination with specific
cancer therapeutics, inducing eosinophil expansion through
the production of IL-5.43 Furthermore, a recent study showed
that anti-CTLA4 treatment in a breast cancer model induces
tumor vasculature normalization and increased responsiveness
to the treatment through eosinophil infiltration.44
Concerning our report, it is the largest series of breast
cancer patients actually reported in literature, focusing on
circulating eosinophil predictive and prognostic power in var-
ious subtypes and treatment settings. Only two articles were
published on breast cancer previously, showing opposite
results, even though they were conducted on different popula-
tions, i.e. on all breast cancer subtypes in one paper and only
on HER2-positive patients in the other one.8,9
In our study, we observed a better prognosis for patients
with a higher REC at baseline, especially in patients not treated
with chemotherapy or with anti-HER2 drugs. This is consistent
with previous data on melanoma, in which the authors
observed a benefit for patients with REC ≥ 1.5% treated with
immunotherapy, but not for patients treated with
chemotherapy.18 Patients treated with trastuzumab generally
also receive chemotherapy, so we can consider the differences
observed in the group receiving or not trastuzumab as
a reflection of what observed for patients receiving or not
chemotherapy. The lower magnitude of benefit in patients
receiving chemotherapy could be explained by its effect on
bone marrow, which leads to a lower production and differ-
entiation of white blood cells, with a consequent lower number
of circulating eosinophils during anticancer treatment. This
hypothesis should be tested on preclinical models.
Interestingly, we observed in the subgroup of patients
younger than 65-y-old a statistically significant benefit in TTF
and in BCSS for patients with higher REC. For older patients,
we observed the same trend of benefit, but the results were not
statistically significant. This is probably due to the aging of
immune system, which includes some changes that lead to an
increased vulnerability of elderly people and probably to
a lower anticancer activity.45
As expected, RLC is also associated with a better survival.
The survival curves for TTF and BCSS show a wider separation
considering RLC than REC. This is probably due to the stron-
ger activity of lymphocytes against cancer, due to their known
direct cytotoxic activity and for their higher frequency com-
pared to eosinophils. Eosinophils seem, in fact, to be cells able
to cooperate with other immune cells, such as lymphocytes,
and acting by means of different mechanisms, as described
above. Another possible explanation of the broad separation
of the curves is the small sample size in the RLC-low group of
only 53 patients, that could allow to identify a small percentage
of patients with a very poor prognosis. Altogether, lymphocytes
are not the only effector in cancer defense and the aim of our
study is to explore the role of eosinophils as immune cells.
Based on our results it seems that eosinophils act synergistically
with lymphocytes. Thus, the combined parameter ELP has
been proposed as a predictive and prognostic biomarker in
hormone receptor-negative/HER2-positive and in TNBC, in
our previous paper, and its value has been confirmed on all
the subtypes in the present retrospective analysis.26 The use of
the ELP is an innovative way to present the data, not previously
proposed by other researchers. We think, in fact, that the use of
product could maximize the effect of two biomarkers asso-
ciated with a good outcome. Conversely, the use of a ratio
can mask the positive effect of a variable, if the one at the
denominator increases proportionally more than that at the
numerator. This is not the case of the commonly used neutro-
phil to lymphocyte ratio, considering the pro-tumoral activity
of neutrophils.46
In our study, we observed not only an association between
relative eosinophil count and survival but also with relapse.
Figure 3. Scatter dot plot of REC at different timepoints. Abbreviation: REC, Relative Eosinophil Count; y, year; FUP, Follow-up. (a) Scatter dot plot for the REC in the
group of 741 patients without relapse at six different timepoints: baseline, after surgery, at 1, 2, 5 and 10 y of follow-up. (b) Scatter dot plot for the REC in the group of
189 patients with relapse at seven different timepoints: baseline, after surgery, at 1, 2, 5 and 10 y of follow-up and at relapse. The p value reported on each figure is
calculated by Friedman test.
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This result has not been confirmed in the multivariate analysis,
which means that another factor, such as lymph node involve-
ment has a more important weight on the risk of recurrence.
The same observation derives from the analysis of data on
relative lymphocyte count, that are predictive of relapse in
univariate analysis, but not in multivariate analysis.
Another interesting observation from our study concerns the
variation of eosinophil count during the follow-up, with a lower
count at diagnosis and at relapse, compared to the post-surgery
timepoint and to the count during the cancer-free follow-up. We
reported the same results in a previous study performed in
a small cohort of hormone receptor-negative/HER2-positive
and in TNBC treated with neoadjuvant chemotherapy.26 Here
we observed these variations in a larger cohort, including all the
breast cancer subtypes and other treatment settings. Interestingly,
these variations are confirmed also when breast cancer subtypes
are considered separately. According to this data, it seems that the
presence of cancer could modify the relative eosinophil count,
with a lower number of eosinophils in the presence of cancer.
Moreover, in the group of patients classified as REC-high we
observed a larger proportion of tumor with low-Ki67 and
Luminal A. This should not be considered a disproportion in
the group analyzed, but more likely seems to be an intrinsic
characteristic of cancer, in which unfavorable factors are asso-
ciated with lower REC at baseline. The REC variation observed
could be linked to a tumor infiltration by the eosinophils or to
a modification of eosinophil expansion and differentiation modu-
lated by the cancer and should be investigated in in vivo models.
This study has the weakness to be retrospective, with
a heterogeneous population and type of treatment. Conversely,
the advantages of the study are the large sample size and to be
focused on an innovative scientific issue. The variations of the
circulating eosinophils reported in this work could therefore
either be a consequence of the systemic perturbations caused
by the disease or play an active role in the tumor development
and/or response to treatment. The eosinophils could in fact not
only be a simple biomarker but also a potential target for antic-
ancer therapy. More studies are mandatory to better clarify their
role in breast cancer: from preclinical studies with the aim to
decipher the molecular interaction between eosinophils and
cancer and to test the effect of a modulation of eosinophil
count on cancer development, to prospective observational stu-
dies on breast cancer patients, to analyze the correspondence
between circulating and tumor tissue eosinophils.
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